On Wednesday, July 13, 2022, Infosys Ltd signed a definitive agreement to acquire BASE life science based in Denmark, which is a leading technology and consulting firm in the life sciences industry, for around 111 million dollars. The acquisition is expected to close during the second quarter of the financial year 2023.
Infosys said, the acquisition shows their commitment to help global life sciences companies to realize business value from the cloud digital platforms and data to increase the speed of the clinical trials and scaling drug development, which is positively impacting the lives and achieving better health outcomes.
The life sciences vertical is contributing 6.6 percent to the total revenues of Infosys and it increased by 16.2 percent year-on-year in a constant currency for the quarter ending March 2022.
Infosys said BASE will bring domain experts with medical, commercial, digital marketing, clinical, quality, and regulatory know-how of the company. BASE has a string focus on the artificial intelligence (AI) and data, and the ability to bridge and mix the business logic and technology, along with driving the insights for better health outcomes.
Ravi Kumar S, president of Infosys, said this acquisition is augmenting deep life sciences expertise of Infosys, and also expanding their footprint further in the Nordics region and across Europe, and scaling their transformation capabilities with industry solutions based on cloud technology.
Ram is a leading news contributor for IndustryWatch24 and specialises in writing about technology. His enthusiasm for the most recent technological advancements, such as Bitcoin and AI technology, among others, is evident in the most recent industry coverage he offers. He currently presents his analysis of popular business and technological fields, which gives his writing a present and unique perspective.